Marlene Haffner
Amministratore Delegato presso Haffner Associates LLC
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Alistair Duncan | M | - |
viDA Therapeutics, Inc.
 viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | 16 anni |
| Christopher R. McMaster | M | - |
DeNovaMed, Inc.
 DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 18 anni |
| Donald F. Weaver | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 18 anni |
| Gail Wilensky | M | 80 |
Uniformed Services University of the Health Sciences
| - |
| David Granville | M | - |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | 16 anni |
| Robert P. Ryan | M | - |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | 8 anni |
| David M. Byers | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 18 anni |
| Christopher J. Barden | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
| Esteban Santos | M | 56 | 17 anni | |
| Julia G. Levy | M | 89 |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
| Gerald H. Sokol | M | 81 |
Uniformed Services University of the Health Sciences
| - |
| Brooks D. Cash | M | - |
Uniformed Services University of the Health Sciences
| - |
| George Peoples | M | - |
Uniformed Services University of the Health Sciences
| - |
| Fan Wu | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
| Dominque Bélanger | M | - |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
| Phil Skolnick | M | 77 |
Uniformed Services University of the Health Sciences
| - |
| Marcia Taylor | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | 13 anni |
| James R. Rundell | M | - |
Uniformed Services University of the Health Sciences
| - |
| Ronald Blanck | M | 82 |
Uniformed Services University of the Health Sciences
| 16 anni |
| Charles Rice | M | - |
Uniformed Services University of the Health Sciences
| 19 anni |
| Asa D. Morton | M | - |
Uniformed Services University of the Health Sciences
| - |
| Mike A. Royal | M | 70 |
Uniformed Services University of the Health Sciences
| - |
| Michael B. Knable | M | - |
Uniformed Services University of the Health Sciences
| - |
| Sergey V. Sheleg | M | - |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | 22 anni |
| Donald W. Campbell | M | 83 |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
| Vicki L. Morgan | F | - |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
| Lidija Marusic | M | - |
DeNovaMed, Inc.
DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada. | - |
| Gosse Bote Bruinsma | M | 69 |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | - |
| Michael Johns | M | 82 |
Uniformed Services University of the Health Sciences
| - |
| Sheila Burke | F | 73 |
Uniformed Services University of the Health Sciences
| - |
| Shiu Fei Ling | M | 67 |
Uniformed Services University of the Health Sciences
| 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Gili Cohen | M | 57 |
Bioblast Pharma Ltd.
 Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 3 anni |
| Pamela Wapnick | F | 58 | 9 anni | |
| Dennis Fenton | M | 72 | 27 anni | |
| Colin Foster | M | 61 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 2 anni |
| Udi Gilboa | M | 57 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 5 anni |
| Ran Weinstock | M | - |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Tomer Yossef | M | - |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Robert Friedman | M | 68 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 2 anni |
| Oren Elmaliah | M | 40 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Joseph Newell | M | 54 | 7 anni | |
| William P. Sheridan | M | 69 | 5 anni | |
| Thomas Zindrick | M | 65 | 8 anni | |
| Andreas Grauer | M | 63 | - | |
| Vasant Prakash Gandhi | M | - | 5 anni | |
| Eyal Gibor | M | 66 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Minnie Baylor-Henry | F | 76 |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | 8 anni |
| John Moriarty | M | 56 | 6 anni | |
| Nathan Hardy | M | 48 | 10 anni | |
| Ronen Twito | M | 49 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Marco Renoldi | M | 67 | 3 anni | |
| Isaac Krymolowski | M | 61 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | - |
| Michael Burshtine | M | 60 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 4 anni |
| François de Carbonnel | M | 78 | 10 anni | |
| Chaime Orlev | M | 53 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 1 anni |
| Vance D. Coffman | M | 79 | 9 anni | |
| Fredric D. Price | M | 78 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 6 anni |
| Cynthia Flowers | F | 64 | 5 anni | |
| Jin Long Chen | M | 61 | 4 anni | |
| Thomas Dubin | M | 62 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | 3 anni |
| Lauro A. González Moreno | M | 62 | - | |
| Timothy Powers | M | 58 | 5 anni | |
| Winston Kung | M | 48 | 3 anni | |
| Diane Parks | F | 71 | 7 anni | |
| Shamim Ruff | F | 64 | 4 anni | |
| James Scott Whitehurst | M | 58 | 8 anni | |
| Randal A. Hassler | M | 66 | 12 anni | |
| Steven J. Ruhl | M | - | - | |
| Rizwana F. Sproule | M | 61 | 6 anni | |
| Richard Nanula | M | 63 | 6 anni | |
| David Essayan | M | - | 4 anni | |
| George G Nomikos | M | - | 1 anni | |
| Sesha Neervannan | M | 56 | 8 anni | |
| Jonathan Leff | M | 66 | 5 anni | |
| Donna French | M | 59 | 15 anni | |
| Adrian Otte | M | - | 11 anni | |
| Michael Wittekind | M | 69 | 4 anni | |
| Riccardo Perfetti | M | 64 | 3 anni | |
| Jude Dinges | M | - | - | |
| Wayne A. Davey | M | - | 3 anni | |
| H. Christian Fibiger | M | 80 | 4 anni | |
| Warren Wayne Myers | M | 62 | 10 anni | |
| Kevin L. Stark | M | - | 15 anni | |
| Fanesca Young | M | - | 2 anni | |
| Jason Chen | M | - | 2 anni | |
| Robert M. Brenner | M | 56 | 9 anni | |
| Kurt Gustafson | M | 55 | 18 anni | |
| Hui Tian | M | - | 9 anni | |
| Alex Virgilio | M | - | 4 anni | |
| Adrian Haigh | M | 65 | 5 anni | |
| Richard Benton Phillips | M | 70 | 2 anni | |
| Richard Paulson | M | 56 | 10 anni | |
| Ellen Feigal | M | 69 | 3 anni | |
| Lisa Guttman | F | - | 7 anni | |
| Marisa Co | F | - | 10 anni | |
| Krishna R. Polu | M | 50 | 2 anni | |
| Vimal Srivastava | M | 58 | 3 anni | |
| Lisa A. Evrén | F | - | 5 anni | |
| Urte Gayko | M | 53 | 9 anni | |
| Donald B. Rice | M | 83 | 7 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 71 | 71.00% |
| Canada | 15 | 15.00% |
| Israele | 14 | 14.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Marlene Haffner
- Contatti personali
